Available Brands
Did you find this information helpful?
Author Details

Written By
P. Thirumal Reddy
B. Pharm

Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 31 Mar 2026 | 09:30 AM (IST)

Want to know more?
Read Our Editorial Policy
Quick Summary
TELMISARTAN,NEBIVOLOL
Last updated on 31 Mar 2026 | 09:30 AM (IST)
TELMISARTAN,NEBIVOLOL
Background and Date of approval TELMISARTAN,NEBIVOLOL
Telmisartan + nebivolol is approved for medical use, to treat hypertension (high blood pressure).
Uses of TELMISARTAN,NEBIVOLOL
Telmisartan + nebivolol is used to treat hypertension.
How is TELMISARTAN,NEBIVOLOL administered?
Telmisartan + nebivolol is available as respules for inhalation in nebulizer. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition.
Side Effects of TELMISARTAN,NEBIVOLOL
The common side effects that are experienced while you are on the treatment with telmisartan + nebivolol are headache, dizziness, tiredness, slow heartbeat, weakness, increased potassium level in the blood, decreased blood pressure, cold extremities, an unusual itching or tingling feeling,diarrhea, constipation, nausea, shortness of breath, swollen hands or feet, stomach upset, nightmares, forgetfulness, difficulty falling asleep. If you have angioedema (swelling of skin), allergic reaction, with a skin eruption speak with your doctor immediately.
Warnings
Before starting treatment, inform your doctor if you have allergies to Telmisartan or Nebivolol, a history of heart disease, diabetes, low blood pressure, Raynaud's disease, or Prinzmetal angina. Before treatment with Telmisartan+ Nebivolol, let your physician know if you are experiencing any allergic reaction to Telmisartan or Nebivolol and its ingredients.
Precautions
Report to your physician if you have kidney or severe liver diseases, heart rhythm problems, low blood pressure, elevated potassium level in the blood, raised aldosterone level, diabetes, asthma, and renal artery stenosis (narrowing of the blood vessels to one or both kidneys). Hence, your doctor may regularly monitor your blood pressure, electrolytes, and potassium level in your blood at regular intervals. It should not be given to children less than 12 years of age.
Word of Advice
 It is advised to monitor your blood pressure regularly. It would be best to have potassium and electrolytes check-ups while taking Telmisartan+ Nebivolol to prevent complications. Get up slowly while rising from a lying or sitting position, as this medicine may cause dizziness. Taking a low-salt diet and regular exercise is recommended for better results. Avoid smoking and alcohol consumption while taking this medication.
Frequently Asked Questions
Q1.
Is children use Telmisartan+ Nebivolol?
No, Telmisartan+ Nebivolol is not recommended for children less than 12 years of age.
Q2.
What happens when I stop taking Telmisartan+ Nebivolol?
Sudden withdrawal of Telmisartan+ Nebivolol may raise your blood pressure and increase the risk of heart failure. Hence, it is necessary to consult your doctor before withdrawing this medication.
Q3.
What happens if I take too much Telmisartan+ Nebivolol?
If you take more Telmisartan+ Nebivolol, that may cause slow heartbeat (bradycardia), low blood pressure with fainting (hypotension), breathlessness such as in asthma (bronchospasm), and acute heart failure.
Q4.
Is Telmisartan+ Nebivolol safe during pregnancy?
No, Telmisartan+ Nebivolol should not be used during pregnancy because it may cause harmful effects on the developing fetus.
Q5.
Can Telmisartan+ Nebivolol cause shortness of breath?
Yes, Telmisartan+ Nebivolol can cause shortness of breath in some people. You must inform your physician if these symptoms disturb or worsen you.
References
- KD Tripathi, Essentials of Medical Pharmacology, Antihypertensive Drugs, 7th Edition, 2018, 561-564.
- Accord Healthcare Limited., Electronic Medicines Compendium (EMC), [Revised on April 2022] [Accessed 19th Sept 2023] https://www.medicines.org.uk/emc/files/pil.5828.pdf
- Boehringer Ingelheim Ltd., Electronic Medicines Compendium (EMC), [Revised on April 2021] [Accessed on 19th Sept 2023], https://www.medicines.org.uk/emc/files/pil.3165.pdf
- Boehringer Inhelheim International GmbH & Co., US Food and Drug Administration, [ Revised on May 2011] [ Accessed on 19th Sept 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/020850s011lbl.pdf
Disclaimer
The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.






